What are the recent financial highlights of SUN PHARMA ADV.RES.CO.LTD?

SUN PHARMA ADV.RES.CO.LTD recently reported a total revenue of ₹61.14 Cr and a net profit margin of 0%. These metrics reflect the company’s consistent financial performance.

What are the key financial metrics of SUN PHARMA ADV.RES.CO.LTD?

Key financial metrics include a trailing P/E ratio of , forward P/E of 2.5296028, book value of ₹-2.386, price-to-book ratio of -58.734283, and a market capitalization of ₹45.48 billion.

What does SUN PHARMA ADV.RES.CO.LTD do?

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Sparc

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Sparc

Latest updates related to Sparc

Sr No.	Title	Sentiment
1	Trade Spotlight: How should you trade Canara Bank, Aether Industries, SPARC and others? Moneycontrol	🔄
2	Trending Stocks: How should you trade Gensol Engineering, Inox Wind & SPARC on Monday The Economic Times	🔄
3	Sparc Electrex Hits 52-Week Low Amid Broader Market Downturn and Weak Fundamentals MarketsMojo	🔄
4	Sparc Technologies to Host Investor Webinar on Green Hydrogen and Graphene Innovations TipRanks	🔄
5	Baker McKenzie Legal Advisor to Sparc Group in its Bond Issuance of SEK 1.1 billion Baker McKenzie	🔄
6	SPARC Q2 Results \| Net loss widens to ₹107 crore, revenue dives 39% to ₹13 crore CNBCTV18	🔄
7	Sparc Electrex Faces Ongoing Challenges Amid Broader IT Hardware Sector Recovery MarketsMojo	🔄
8	Sparc Technologies Secures Key Trial Agreement with BHP Mitsubishi Alliance ChemAnalyst	🔄
9	APCCC Diagnostics 2025: PCWG4 and SPARC - Including How to Define Progression on PSMA PET Imaging UroToday	🔄
10	SPARC up 12% ahead of update on clinical programs, R&D pipeline this week Moneycontrol	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Loading...

Loading...

Stock News - Sparc

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Credit ratings

Concalls

Explore More Stocks